【摘要】 目的 研究喹硫平对双相抑郁障碍患者外周血PDLIM5 mRNA表达的影响。方法 选择21例双相抑郁障碍患者(患者组)及23名患者的健康一级亲属(对照组),患者组给予喹硫平治疗,分别在治疗前及治疗2周、4周和8周对受试者进行阿斯伯格抑郁评定量表(MADRS)评估,检测外周血PDLIM5mRNA的表达量。结果 治疗2周和4周后,患者组MADRS评分与治疗前相比差异无统计学意义(P>0.05);治疗8周后,患者组MADRS评分明显下降,与治疗前相比差异有统计学意义(P<0.01)。治疗前,患者组外周血中PDLIM5 mRNA水平显著低于对照组(P<0.01);治疗2周和4周后,患者组外周血PDLIM5 mRNA表达量与治疗前相比无明显变化,治疗8周后患者组外周血PDLIM5 mRNA表达量有所增加,与治疗前相比差异有统计学意义(P<0.05)。喹硫平治疗前后患者组MADRS总分与外周血PDLIM5mRNA表达水平无明显相关性(P>0.05)。结论喹硫平可以有效改善双相抑郁障碍患者的抑郁症状,但不影响外周血PDLIM5表达。更多还原

【Abstract】 Objectives To investigate the effect of quetiapine on the expression of PDLIM5 mRNA in peripheral blood of patients with bipolar depression.Methods Totals of 21 bipolar depression patients(patient group)and 23 one-level relatives without mental health were recruted.Patients were treated with quetiapine for 8 weeks.Montgomery and Asperger Depression Rating Scale(MADRS)was evaluated and PDLIM5 mRNA expression level in peripheral blood was also tested before treatment and 2 weeks,4 weeks,8 weeks after treatment respectively.Results After 2 and 4 weeks of quetiapine treatment,there was no significant difference in MADRS score in patient group before and after treatment(P>0.05).After 8 weeks treatment,MADRS scores in patient group were significantly decreased,and the difference was statistically significant(P<0.01).Before treatment,PDLIM5 mRNA levels in peripheral blood of patient group were significantly lower than those in control group(P<0.01).After 2 and 4 weeks treatment,the expression of PDLIM5 mRNA in peripheral blood of patient group showed no significant change compared with that before treatment.The expression of PDLIM5 mRNA in peripheral blood of patient group increased after 8 weeks treatment,and the difference was statistically significant(P<0.05).There was no significant correlation between the total score of MADRS and the expression of PDLIM5 mRNA in peripheral blood of patients with bipolar depression before and after treatment,and the difference was not statistically significant(P>0.05).Conclusions Quetiapine can effectively improve the depressive symptoms of patients with bipolar depression but does not affect the expression of PDLIM5 in peripheral blood.更多还原